Physician profile
James Bailes
NPI 1891759031
$4,627.32
in general payments reported to CMS, 2019-2025
21 companies · $392 in 2025
The $392 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $172 · 2021: $1,715 · 2022: $1,456 · 2023: $174 · 2024: $333 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,021.68 | 2021-2024 | Minimed 780g |
| Insulet Corporation | $520.12 | 2019-2025 | Omnipod |
| Medtronic Minimed, INC. | $268.08 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $144.12 | 2021-2022 | |
| Dexcom, INC. | $110.80 | 2019-2022 | |
| Abbvie INC. | $99.04 | 2019-2024 | |
| Tandem Diabetes Care, INC. | $81.56 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Collegium Pharmaceutical, INC. | $69.64 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $36.75 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $31.41 | 2025 | Fanapt |
| Sequel Med Tech, LLC | $30.65 | 2025 | Twiist |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.34 | 2025 | Caplyta |
| Abbott Laboratories | $28.16 | 2023-2025 | Freestyle Libre 3 |
| Indivior INC. | $26.69 | 2024 | Sublocade |
| Sanofi-Aventis U.S. LLC | $24.77 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $24.11 | 2022 | |
| Corium, LLC | $19.00 | 2023 | Azstarys |
| Xeris Pharmaceuticals, INC. | $17.86 | 2024 | Gvoke Hypopen |
| Ironshore Pharmaceuticals INC. | $16.99 | 2024 | |
| Braeburn INC. | $15.57 | 2023 | Brixadi |
| Lilly USA, LLC | $11.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bailes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.